For long, cardiovascular diseases have been spearheading gene testing and this trend is estimated to go on in the near future. Disorders of heart can be passed to children from parents through their genes, i.e. the disease can be inherited. Growing prevalence of cardiovascular disease and the nature of it is likely to play an important role in the expansion of the global cardiovascular genomic diagnostics market over the timeframe of analysis, from 2020 to 2030. This type of testing assists in the detection of various diseases, such as congenital heart diseases and aortopathy. Genetic disorders adversely influence the development of blood vessels, thereby leading to congenital heart diseases. This type of testing is useful in detecting the chances of family members contacting heart problems. The technology is utilized for the purpose of a cardiology genomic testing known as Next generation Sequencing (NGS). In addition to that, this technology is able to read genetic content that assists in detecting the changes in the sequence of DNA. Pathogens are considered responsible for mutations that are linked with the conditions of heart.
Test type, disease indication, technological platform, end user, and region are the five parameters that have been used for the classification of the global cardiovascular genomic diagnostics market.
The global cardiovascular genomic diagnostics market is considered moderately fragmented. The players in the market are taking up advanced techniques for the purpose of development of cardiovascular genomic diagnostics. This will further assist in diversifying the product offerings and strengthening geographical presence across the globe. One of the important and relevant developments pertaining to this market is mentioned as below
Some of the prominent organizations in the global cardiovascular genomic diagnostics market comprise the below-mentioned:
The global cardiovascular genomic diagnostics market is characterized by the presence of the following restraints, drivers, and opportunities.
A rise in the prevalence of different types of heart diseases, such as congenital heart disease, atherosclerosis, and cardiac arrhythmias is likely to bolster growth of the global cardiovascular genomic diagnostics market over the timeframe of analysis, from 2020 to 2030. In accordance to the findings of the Centers for Disease Control and Prevention (CDC), in 2017 nearly 365,914 people are killed by the coronary heart disease and it is one of the leading causes of death worldwide. It is also estimated that around one in every 200 individuals inherit heart diseases from their family members. Such high prevalence of heart diseases is anticipated to encourage growth of the global cardiovascular genomic diagnostics market in the years to come.
In addition, increased prevalence of unhealthy lifestyle and eating practices is estimated to drive the increased prevalence of cardiovascular diseases. Cardiovascular genomic diagnostics assist in the management, prognosis, and diagnosis of heart-related illnesses, which is likely to drive the demand for this diagnostic in the years to come.
In the global cardiovascular genomic diagnostics market, North America is estimated to emerge as one of the leading regions. Such growth of the North America market is ascribed to the technological progress made in the sector. Along with that, strict regulations pertaining to safety and patient care in the region is expected to foster growth of the market in North America.